Navigation Links
Resverlogix Activates First Site for ASSURE 1 Clinical Trial
Date:2/25/2010

compared to placebo control. In half of the patients a change in atherosclerosis will be assessed, i.e. change in plaque volume and plaque composition. The primary objective of this study is to determine the 3 month effect of RVX-208 on change in the plasma levels of ApoA-l in patients with a recent ACS event who require coronary angiography versus placebo. The secondary objectives for this study include assessing the safety and tolerability of the drug through evaluation of adverse events as well as to evaluate the effect of RVX-208 on other lipid parameters.

"There are a number of people who are very pleased that we are able to announce the beginning of our IVUS study. Much planning has been undertaken with our international experts who reside on our IVUS Steering Committee and Clinical Advisory Committee. We are pleased to be able to bring RVX-208 to acute coronary syndrome patients, a group that presents with high cardiovascular risk," said Dr. Allan Gordon, Senior Vice President Clinical Development of Resverlogix Corp.

Resverlogix clinical program is expanding. In unrelated news Resverlogix is pleased to announce today the appointment of Ms. Tina Rarick to the position of Vice President Project Management & Business Operations. Tina recently joined Resverlogix after working for the past six years as a Global Project Manager for Roche Pharmaceuticals. Previous to this Tina was with several pharmaceutical firms including Schering-Plough and SUGEN/Pharmacia. Earlier in her career Ti
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Resverlogix Completes Patient Recruitment for ASSERT Trial
2. Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors
3. Resverlogix Presenting at Biotech Showcase
4. Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial
5. Resverlogix Updates Shareholders on Accelerated Clinical Trial Plan
6. Resverlogix Appoints A. Brad Cann as Chief Financial Officer
7. Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
8. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
9. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
10. Resverlogix Provides Quarterly Update
11. Resverlogix Board of Directors Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015 Biofertilizers stimulate microbial activities in ... and phosphorous through the activities in the soil or ... due to the stress on reducing environmental pollution and ... report defines and segments the bio fertilizers market with ...
(Date:1/22/2015)... COLUMBIA, Md. (PRWEB) January 22, 2015 ... of its new UV-1280 multipurpose UV-visible spectrophotometer. Offering ... compact, high-quality instrument is ideal for applications in ... and life science. , The user-friendly UV-1280 enables ...
(Date:1/22/2015)... (PRWEB) January 21, 2015 Cambridge Semantics, the ... technology, today announced that 2014 was a record-breaking year across ... capabilities of the Anzo Smart Data Platform and our Smart ... utilize insights from diverse data which led to record growth ...
(Date:1/22/2015)... California (PRWEB) January 22, 2015 Pipette.com ... Offer to their comprehensive portfolio of Eppendorf products. ... customers to purchase a Centrifuge 5424/5424 R and receive ... of either Eppendorf Research plus or Eppendorf Reference 2 ...
Breaking Biology Technology:Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 2Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 3Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 4Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2Cambridge Semantics Announces Record Results for 2014 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2
... Presentation Scheduled for Monday, March 17th at 11:30am ET, ... KERX ) today announced that I. Craig Henderson, ... Vice President,Medical Affairs, are scheduled to present at the ... The presentation, which will take place on Monday, ...
... Phase 2 Clinical Trial in ... ... today financial results for the year ended December,31, 2007, and highlighted the ... ), During 2007, the Company achieved the following corporate milestones:, ...
... for ... cars, phones, computers, ARGONNE, Ill., ... Laboratory and Toda Kogyo Corp. (Toda) of Japan have,reached a ... patented composite cathode materials for lithium-ion,batteries, which result in longer-lasting, ...
Cached Biology Technology:Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference 2Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 2Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 3Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 4Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 5Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 6Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 7Argonne's Lithium-Ion Battery Technology to be Commercialized by Japan's Toda Kogyo 2Argonne's Lithium-Ion Battery Technology to be Commercialized by Japan's Toda Kogyo 3
(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to ... State of Washington,s Department of Licensing, in ... central issuance system for driver,s licenses and identification cards to ... and development will start in January 2015, with enrollment and ...
(Date:1/22/2015)... Jan. 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), ... crowdfunding campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz ... production capacity to meet customer demand. ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by ...
(Date:1/22/2015)... 15, 2015  BellBrook Labs, a leader in high ... launch of a TR-FRET (time resolved Forster resonance ... Assay, a high throughput screening assay for glycosyltransferases ... allow for sensitive detection of hundreds of human ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... have a well-earned reputation for being dopey. Sleeping 19 hours ... remaining 5 hours, there doesn,t seem to be much time ... the mating season. Then the males begin bellowing. Benjamin Charlton ... bellow to attract females and to intimidate other males. But ...
... structure rich, poor and sometimes middle instead of ... to Stanford University researchers, it is the very inequities of ... spread of those societies and the displacement of more egalitarian ... researchers used a computer simulation to compare demographic stability and ...
... NCForest Service Southern Research Station (SRS) scientists recently ... (Coweeta) in Western North Carolina to examine the ... the changing weather conditions forecast for the future. ... the journal Ecological Applications, the analysis examines the ...
Cached Biology News:Koalas' bellows boast about size 2Suffering of the poor may have helped societies with class structures spread across globe 2Managing future forests for water 2
GBL Antibody...
Dnase and Rnase free...
TLN2 Antibody...
Mouse monoclonal [0.N.305] to G protein alpha - BSA and Azide free ( Abpromise for all tested applications). Antigen: Partially purified G protein alpha from rat brain. Entrez GeneID: 2778 ...
Biology Products: